RxDoctor Payments Data

Joseph Poole

Cardiovascular Disease · Athens, GANPI 1699935106

Payments from drug & device makers

$1,243in general payments, 2019–2025

Across 70 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$160
  • Novartis$139
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$116
  • Amgen$106
  • Johnson & Johnson$91
  • Boehringer Ingelheim$90
  • plus $542 from 12 others

What the payments were for

  • Food & beverage$1,243100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,243 in reported general payments places this provider in the 35th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$247,768
Medicare patients
2,010
Services billed
4,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban508$548,905
XareltoRivaroxaban130$141,007
EntrestoSacubitril/Valsartan63$66,772
Nebivolol Hcl585$27,152
JardianceEmpagliflozin29$26,067
Repatha SureclickEvolocumab18$24,076
BrilintaTicagrelor14$15,267
Ranolazine ErRanolazine146$13,700
Diltiazem 24hr Er (Cd)Diltiazem Hcl310$5,662
Metoprolol Succinate407$4,899
Atorvastatin Calcium452$4,265
Isosorbide Mononitrate ErIsosorbide Mononitrate262$3,645
Potassium Chloride181$2,779
Torsemide167$2,644
ClopidogrelClopidogrel Bisulfate240$2,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$548,905508 claims
Johnson & JohnsonXarelto$91$141,007130 claims
NovartisEntresto$139$66,77263 claims
Boehringer IngelheimJardiance$90$26,06729 claims
AstraZenecaBrilinta$38$15,26714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →